ACSL4 expression did not significantly affect recurrence rates in HCC patients (P = 0.549, Fig. S2e); however, its presence in primary tumors was associated with poorer survival after recurrence, especially among those experiencing early recurrence within 2 years (P = 0.033, Fig. S2f). This evidence concerns the gene ACSL4 and hepatocellular carcinoma.